Injectable Bulking Agent to Treat Postprostatectomy Urinary Incontinence: A Safety and Effectiveness Pilot Study

Objectives. To evaluate the safety and effectiveness of the injectable bulking agent Opsys® (Promedon, Cordoba, Argentina) for treating minimal postprostatectomy stress urinary incontinence (SUI). Patients and Methods. Single-centre, pilot study on ten male patients with SUI, < 30 g urine loss/ 2...

Full description

Saved in:

Bibliographic Details
Published in:	BioMed research international 2018-01, Vol.2018, p.2796967-6
Main Authors:	van Uhm, Janneke I. M., Vermeer, Marloes, Elzevier, Henk W., Noordzij, Joop W., Koldewijn, Evert L., Cornel, Erik B.
Format:	Article
Language:	eng
Subjects:	Aged Argentina Cancer surgery Care and treatment Complications Confidence intervals Consultation Endoscopes Endoscopy Glycerol Hematuria Humans Injection Injections Intervention Male Medical research Medicine, Experimental Middle Aged Patients Pilot Projects Prostate cancer Prostatectomy Prostatectomy - methods Questionnaires Safety Safety and security measures Studies Surveys and Questionnaires Treatment Outcome Urethra - drug effects Urinary incontinence Urinary Incontinence, Stress - drug therapy Urine Urology Weight
Online Access:	Request full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objectives. To evaluate the safety and effectiveness of the injectable bulking agent Opsys® (Promedon, Cordoba, Argentina) for treating minimal postprostatectomy stress urinary incontinence (SUI). Patients and Methods. Single-centre, pilot study on ten male patients with SUI, < 30 g urine loss/ 24 h, more than 1 year after radical prostatectomy. Patients were treated by endoscopic transurethral injections of bulking agent in the presphincteric zone of the urethral submucosa. The results were evaluated using a pad weight test to quantify the differences in urine loss at 1, 3, and 6 months after intervention. Subsequently, the results of treatment were also evaluated by International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF), Incontinence Impact Questionnaire (IIQ-7), Urogenital Distress Inventory Short Form (UDI-6-SF), and the Patient Global Impression of Improvement (PGI-I) at 1, 3, and 6 months after intervention. Results. The primary outcome was the absolute result of the 24-hour pad weight test after treatment. Treatment success was defined as
ISSN:	2314-6133 2314-6141